Global Neulasta (Pegfilgrastim) and Biosimilar Market Research Report 2026(Status and Outlook)
Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim.It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.
The global Neulasta (Pegfilgrastim) and Biosimilar market size was estimated at USD 2737.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 6.50% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Neulasta (Pegfilgrastim) and Biosimilar market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Neulasta (Pegfilgrastim) and Biosimilar market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Neulasta (Pegfilgrastim) and Biosimilar market.
Global Neulasta (Pegfilgrastim) and Biosimilar Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Amgen
Viatris
Coherus
Novartis
Pfizer
Amneal Pharmaceutical
Fresenius Kabi
Market Segmentation (by Type)
Brand
Biosimilar
Market Segmentation (by Application)
Hospital
Pharmacy
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Neulasta (Pegfilgrastim) and Biosimilar Market
Overview of the regional outlook of the Neulasta (Pegfilgrastim) and Biosimilar Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neulasta (Pegfilgrastim) and Biosimilar Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Neulasta (Pegfilgrastim) and Biosimilar, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Neulasta (Pegfilgrastim) and Biosimilar market size was estimated at USD 2737.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 6.50% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Neulasta (Pegfilgrastim) and Biosimilar market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Neulasta (Pegfilgrastim) and Biosimilar market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Neulasta (Pegfilgrastim) and Biosimilar market.
Global Neulasta (Pegfilgrastim) and Biosimilar Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Amgen
Viatris
Coherus
Novartis
Pfizer
Amneal Pharmaceutical
Fresenius Kabi
Market Segmentation (by Type)
Brand
Biosimilar
Market Segmentation (by Application)
Hospital
Pharmacy
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Neulasta (Pegfilgrastim) and Biosimilar Market
Overview of the regional outlook of the Neulasta (Pegfilgrastim) and Biosimilar Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neulasta (Pegfilgrastim) and Biosimilar Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Neulasta (Pegfilgrastim) and Biosimilar, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Neulasta (Pegfilgrastim) and Biosimilar
1.2 Key Market Segments
1.2.1 Neulasta (Pegfilgrastim) and Biosimilar Segment by Type
1.2.2 Neulasta (Pegfilgrastim) and Biosimilar Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Neulasta (Pegfilgrastim) and Biosimilar Product Life Cycle
3.3 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Manufacturers (2020-2025)
3.4 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Manufacturers (2020-2025)
3.5 Neulasta (Pegfilgrastim) and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Neulasta (Pegfilgrastim) and Biosimilar Market Competitive Situation and Trends
3.8.1 Neulasta (Pegfilgrastim) and Biosimilar Market Concentration Rate
3.8.2 Global 5 and 10 Largest Neulasta (Pegfilgrastim) and Biosimilar Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR INDUSTRY CHAIN ANALYSIS
4.1 Neulasta (Pegfilgrastim) and Biosimilar Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Neulasta (Pegfilgrastim) and Biosimilar Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Neulasta (Pegfilgrastim) and Biosimilar Market
5.7 ESG Ratings of Leading Companies
6 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2020-2025)
6.3 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Type (2020-2025)
6.4 Global Neulasta (Pegfilgrastim) and Biosimilar Price by Type (2020-2025)
7 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Sales by Application (2020-2025)
7.3 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) by Application (2020-2025)
7.4 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Growth Rate by Application (2020-2025)
8 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET SALES BY REGION
8.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region
8.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region
8.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region
8.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region
8.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region
8.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region
8.3 North America
8.3.1 North America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country
8.3.2 North America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country
8.4.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales by Region
8.5.2 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country
8.6.2 South America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Region
8.7.2 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET PRODUCTION BY REGION
9.1 Global Production of Neulasta (Pegfilgrastim) and Biosimilar by Region(2020-2025)
9.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Region (2020-2025)
9.3 Global Neulasta (Pegfilgrastim) and Biosimilar Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Neulasta (Pegfilgrastim) and Biosimilar Production
9.4.1 North America Neulasta (Pegfilgrastim) and Biosimilar Production Growth Rate (2020-2025)
9.4.2 North America Neulasta (Pegfilgrastim) and Biosimilar Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Neulasta (Pegfilgrastim) and Biosimilar Production
9.5.1 Europe Neulasta (Pegfilgrastim) and Biosimilar Production Growth Rate (2020-2025)
9.5.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Neulasta (Pegfilgrastim) and Biosimilar Production (2020-2025)
9.6.1 Japan Neulasta (Pegfilgrastim) and Biosimilar Production Growth Rate (2020-2025)
9.6.2 Japan Neulasta (Pegfilgrastim) and Biosimilar Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Neulasta (Pegfilgrastim) and Biosimilar Production (2020-2025)
9.7.1 China Neulasta (Pegfilgrastim) and Biosimilar Production Growth Rate (2020-2025)
9.7.2 China Neulasta (Pegfilgrastim) and Biosimilar Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Amgen
10.1.1 Amgen Basic Information
10.1.2 Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Overview
10.1.3 Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
10.1.4 Amgen Business Overview
10.1.5 Amgen SWOT Analysis
10.1.6 Amgen Recent Developments
10.2 Viatris
10.2.1 Viatris Basic Information
10.2.2 Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Overview
10.2.3 Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
10.2.4 Viatris Business Overview
10.2.5 Viatris SWOT Analysis
10.2.6 Viatris Recent Developments
10.3 Coherus
10.3.1 Coherus Basic Information
10.3.2 Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Overview
10.3.3 Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
10.3.4 Coherus Business Overview
10.3.5 Coherus SWOT Analysis
10.3.6 Coherus Recent Developments
10.4 Novartis
10.4.1 Novartis Basic Information
10.4.2 Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Overview
10.4.3 Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
10.4.4 Novartis Business Overview
10.4.5 Novartis Recent Developments
10.5 Pfizer
10.5.1 Pfizer Basic Information
10.5.2 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Overview
10.5.3 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
10.5.4 Pfizer Business Overview
10.5.5 Pfizer Recent Developments
10.6 Amneal Pharmaceutical
10.6.1 Amneal Pharmaceutical Basic Information
10.6.2 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Overview
10.6.3 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
10.6.4 Amneal Pharmaceutical Business Overview
10.6.5 Amneal Pharmaceutical Recent Developments
10.7 Fresenius Kabi
10.7.1 Fresenius Kabi Basic Information
10.7.2 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Overview
10.7.3 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
10.7.4 Fresenius Kabi Business Overview
10.7.5 Fresenius Kabi Recent Developments
11 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET FORECAST BY REGION
11.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast
11.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country
11.2.3 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Region
11.2.4 South America Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Neulasta (Pegfilgrastim) and Biosimilar by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Neulasta (Pegfilgrastim) and Biosimilar by Type (2026-2035)
12.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Neulasta (Pegfilgrastim) and Biosimilar by Type (2026-2035)
12.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Forecast by Application (2026-2035)
12.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT) Forecast by Application
12.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Neulasta (Pegfilgrastim) and Biosimilar
1.2 Key Market Segments
1.2.1 Neulasta (Pegfilgrastim) and Biosimilar Segment by Type
1.2.2 Neulasta (Pegfilgrastim) and Biosimilar Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Neulasta (Pegfilgrastim) and Biosimilar Product Life Cycle
3.3 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Manufacturers (2020-2025)
3.4 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Manufacturers (2020-2025)
3.5 Neulasta (Pegfilgrastim) and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Neulasta (Pegfilgrastim) and Biosimilar Market Competitive Situation and Trends
3.8.1 Neulasta (Pegfilgrastim) and Biosimilar Market Concentration Rate
3.8.2 Global 5 and 10 Largest Neulasta (Pegfilgrastim) and Biosimilar Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR INDUSTRY CHAIN ANALYSIS
4.1 Neulasta (Pegfilgrastim) and Biosimilar Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Neulasta (Pegfilgrastim) and Biosimilar Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Neulasta (Pegfilgrastim) and Biosimilar Market
5.7 ESG Ratings of Leading Companies
6 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2020-2025)
6.3 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Type (2020-2025)
6.4 Global Neulasta (Pegfilgrastim) and Biosimilar Price by Type (2020-2025)
7 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Sales by Application (2020-2025)
7.3 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) by Application (2020-2025)
7.4 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Growth Rate by Application (2020-2025)
8 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET SALES BY REGION
8.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region
8.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region
8.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region
8.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region
8.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region
8.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region
8.3 North America
8.3.1 North America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country
8.3.2 North America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country
8.4.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales by Region
8.5.2 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country
8.6.2 South America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Region
8.7.2 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET PRODUCTION BY REGION
9.1 Global Production of Neulasta (Pegfilgrastim) and Biosimilar by Region(2020-2025)
9.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Region (2020-2025)
9.3 Global Neulasta (Pegfilgrastim) and Biosimilar Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Neulasta (Pegfilgrastim) and Biosimilar Production
9.4.1 North America Neulasta (Pegfilgrastim) and Biosimilar Production Growth Rate (2020-2025)
9.4.2 North America Neulasta (Pegfilgrastim) and Biosimilar Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Neulasta (Pegfilgrastim) and Biosimilar Production
9.5.1 Europe Neulasta (Pegfilgrastim) and Biosimilar Production Growth Rate (2020-2025)
9.5.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Neulasta (Pegfilgrastim) and Biosimilar Production (2020-2025)
9.6.1 Japan Neulasta (Pegfilgrastim) and Biosimilar Production Growth Rate (2020-2025)
9.6.2 Japan Neulasta (Pegfilgrastim) and Biosimilar Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Neulasta (Pegfilgrastim) and Biosimilar Production (2020-2025)
9.7.1 China Neulasta (Pegfilgrastim) and Biosimilar Production Growth Rate (2020-2025)
9.7.2 China Neulasta (Pegfilgrastim) and Biosimilar Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Amgen
10.1.1 Amgen Basic Information
10.1.2 Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Overview
10.1.3 Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
10.1.4 Amgen Business Overview
10.1.5 Amgen SWOT Analysis
10.1.6 Amgen Recent Developments
10.2 Viatris
10.2.1 Viatris Basic Information
10.2.2 Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Overview
10.2.3 Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
10.2.4 Viatris Business Overview
10.2.5 Viatris SWOT Analysis
10.2.6 Viatris Recent Developments
10.3 Coherus
10.3.1 Coherus Basic Information
10.3.2 Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Overview
10.3.3 Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
10.3.4 Coherus Business Overview
10.3.5 Coherus SWOT Analysis
10.3.6 Coherus Recent Developments
10.4 Novartis
10.4.1 Novartis Basic Information
10.4.2 Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Overview
10.4.3 Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
10.4.4 Novartis Business Overview
10.4.5 Novartis Recent Developments
10.5 Pfizer
10.5.1 Pfizer Basic Information
10.5.2 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Overview
10.5.3 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
10.5.4 Pfizer Business Overview
10.5.5 Pfizer Recent Developments
10.6 Amneal Pharmaceutical
10.6.1 Amneal Pharmaceutical Basic Information
10.6.2 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Overview
10.6.3 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
10.6.4 Amneal Pharmaceutical Business Overview
10.6.5 Amneal Pharmaceutical Recent Developments
10.7 Fresenius Kabi
10.7.1 Fresenius Kabi Basic Information
10.7.2 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Overview
10.7.3 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Market Performance
10.7.4 Fresenius Kabi Business Overview
10.7.5 Fresenius Kabi Recent Developments
11 NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MARKET FORECAST BY REGION
11.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast
11.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country
11.2.3 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Region
11.2.4 South America Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Neulasta (Pegfilgrastim) and Biosimilar by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Neulasta (Pegfilgrastim) and Biosimilar by Type (2026-2035)
12.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Neulasta (Pegfilgrastim) and Biosimilar by Type (2026-2035)
12.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Forecast by Application (2026-2035)
12.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT) Forecast by Application
12.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Type (M USD)
Table 4. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Application
Table 5. Neulasta (Pegfilgrastim) and Biosimilar Market Size Comparison by Region (M USD)
Table 6. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neulasta (Pegfilgrastim) and Biosimilar as of 2025)
Table 11. Global Market Neulasta (Pegfilgrastim) and Biosimilar Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Neulasta (Pegfilgrastim) and Biosimilar Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Neulasta (Pegfilgrastim) and Biosimilar Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (K MT)
Table 27. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Type (M USD)
Table 28. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT) by Type (2020-2025)
Table 29. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2020-2025)
Table 30. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) by Type (2020-2025)
Table 31. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Type (2020-2025)
Table 32. Global Neulasta (Pegfilgrastim) and Biosimilar Price (USD/KG) by Type (2020-2025)
Table 33. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT) by Application
Table 34. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Application
Table 35. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2020-2025) & (K MT)
Table 36. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2020-2025)
Table 37. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Application (2020-2025) & (M USD)
Table 38. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application (2020-2025)
Table 39. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Growth Rate by Application (2020-2025)
Table 40. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2020-2025) & (K MT)
Table 41. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2020-2025)
Table 42. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region (2020-2025) & (M USD)
Table 43. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region (2020-2025)
Table 44. North America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2020-2025) & (K MT)
Table 45. North America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2020-2025) & (K MT)
Table 47. Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region (2020-2025) & (M USD)
Table 50. South America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2020-2025) & (K MT)
Table 51. South America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region (2020-2025) & (M USD)
Table 54. Global Neulasta (Pegfilgrastim) and Biosimilar Production (K MT) by Region(2020-2025)
Table 55. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Region (2020-2025)
Table 57. Global Neulasta (Pegfilgrastim) and Biosimilar Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Neulasta (Pegfilgrastim) and Biosimilar Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Neulasta (Pegfilgrastim) and Biosimilar Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Neulasta (Pegfilgrastim) and Biosimilar Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Neulasta (Pegfilgrastim) and Biosimilar Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Amgen Basic Information
Table 63. Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 64. Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Amgen Business Overview
Table 66. Amgen SWOT Analysis
Table 67. Amgen Recent Developments
Table 68. Viatris Basic Information
Table 69. Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 70. Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Viatris Business Overview
Table 72. Viatris SWOT Analysis
Table 73. Viatris Recent Developments
Table 74. Coherus Basic Information
Table 75. Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 76. Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Coherus Business Overview
Table 78. Coherus SWOT Analysis
Table 79. Coherus Recent Developments
Table 80. Novartis Basic Information
Table 81. Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 82. Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Novartis Business Overview
Table 84. Novartis Recent Developments
Table 85. Pfizer Basic Information
Table 86. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 87. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Pfizer Business Overview
Table 89. Pfizer Recent Developments
Table 90. Amneal Pharmaceutical Basic Information
Table 91. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 92. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Amneal Pharmaceutical Business Overview
Table 94. Amneal Pharmaceutical Recent Developments
Table 95. Fresenius Kabi Basic Information
Table 96. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 97. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Fresenius Kabi Business Overview
Table 99. Fresenius Kabi Recent Developments
Table 100. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Region (2026-2035) & (K MT)
Table 101. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Region (2026-2035) & (M USD)
Table 102. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2026-2035) & (K MT)
Table 103. North America Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country (2026-2035) & (M USD)
Table 104. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2026-2035) & (K MT)
Table 105. Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country (2026-2035) & (M USD)
Table 106. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Region (2026-2035) & (K MT)
Table 107. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Region (2026-2035) & (M USD)
Table 108. South America Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2026-2035) & (K MT)
Table 109. South America Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country (2026-2035) & (M USD)
Table 110. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2026-2035) & (Units)
Table 111. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country (2026-2035) & (M USD)
Table 112. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Type (2026-2035) & (K MT)
Table 113. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Type (2026-2035) & (M USD)
Table 114. Global Neulasta (Pegfilgrastim) and Biosimilar Price Forecast by Type (2026-2035) & (USD/KG)
Table 115. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT) Forecast by Application (2026-2035)
Table 116. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Type (M USD)
Table 4. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Application
Table 5. Neulasta (Pegfilgrastim) and Biosimilar Market Size Comparison by Region (M USD)
Table 6. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neulasta (Pegfilgrastim) and Biosimilar as of 2025)
Table 11. Global Market Neulasta (Pegfilgrastim) and Biosimilar Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Neulasta (Pegfilgrastim) and Biosimilar Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Neulasta (Pegfilgrastim) and Biosimilar Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (K MT)
Table 27. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Type (M USD)
Table 28. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT) by Type (2020-2025)
Table 29. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2020-2025)
Table 30. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) by Type (2020-2025)
Table 31. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Type (2020-2025)
Table 32. Global Neulasta (Pegfilgrastim) and Biosimilar Price (USD/KG) by Type (2020-2025)
Table 33. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT) by Application
Table 34. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Application
Table 35. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2020-2025) & (K MT)
Table 36. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2020-2025)
Table 37. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Application (2020-2025) & (M USD)
Table 38. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application (2020-2025)
Table 39. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Growth Rate by Application (2020-2025)
Table 40. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2020-2025) & (K MT)
Table 41. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2020-2025)
Table 42. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region (2020-2025) & (M USD)
Table 43. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region (2020-2025)
Table 44. North America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2020-2025) & (K MT)
Table 45. North America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2020-2025) & (K MT)
Table 47. Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region (2020-2025) & (M USD)
Table 50. South America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2020-2025) & (K MT)
Table 51. South America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region (2020-2025) & (M USD)
Table 54. Global Neulasta (Pegfilgrastim) and Biosimilar Production (K MT) by Region(2020-2025)
Table 55. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Region (2020-2025)
Table 57. Global Neulasta (Pegfilgrastim) and Biosimilar Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Neulasta (Pegfilgrastim) and Biosimilar Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Neulasta (Pegfilgrastim) and Biosimilar Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Neulasta (Pegfilgrastim) and Biosimilar Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Neulasta (Pegfilgrastim) and Biosimilar Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Amgen Basic Information
Table 63. Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 64. Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Amgen Business Overview
Table 66. Amgen SWOT Analysis
Table 67. Amgen Recent Developments
Table 68. Viatris Basic Information
Table 69. Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 70. Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Viatris Business Overview
Table 72. Viatris SWOT Analysis
Table 73. Viatris Recent Developments
Table 74. Coherus Basic Information
Table 75. Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 76. Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Coherus Business Overview
Table 78. Coherus SWOT Analysis
Table 79. Coherus Recent Developments
Table 80. Novartis Basic Information
Table 81. Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 82. Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Novartis Business Overview
Table 84. Novartis Recent Developments
Table 85. Pfizer Basic Information
Table 86. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 87. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Pfizer Business Overview
Table 89. Pfizer Recent Developments
Table 90. Amneal Pharmaceutical Basic Information
Table 91. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 92. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Amneal Pharmaceutical Business Overview
Table 94. Amneal Pharmaceutical Recent Developments
Table 95. Fresenius Kabi Basic Information
Table 96. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Overview
Table 97. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Fresenius Kabi Business Overview
Table 99. Fresenius Kabi Recent Developments
Table 100. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Region (2026-2035) & (K MT)
Table 101. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Region (2026-2035) & (M USD)
Table 102. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2026-2035) & (K MT)
Table 103. North America Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country (2026-2035) & (M USD)
Table 104. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2026-2035) & (K MT)
Table 105. Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country (2026-2035) & (M USD)
Table 106. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Region (2026-2035) & (K MT)
Table 107. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Region (2026-2035) & (M USD)
Table 108. South America Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2026-2035) & (K MT)
Table 109. South America Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country (2026-2035) & (M USD)
Table 110. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Country (2026-2035) & (Units)
Table 111. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Country (2026-2035) & (M USD)
Table 112. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Type (2026-2035) & (K MT)
Table 113. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Type (2026-2035) & (M USD)
Table 114. Global Neulasta (Pegfilgrastim) and Biosimilar Price Forecast by Type (2026-2035) & (USD/KG)
Table 115. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT) Forecast by Application (2026-2035)
Table 116. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Neulasta (Pegfilgrastim) and Biosimilar
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD), 2025-2035
Figure 5. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) (2020-2035)
Figure 6. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Neulasta (Pegfilgrastim) and Biosimilar Product Life Cycle
Figure 13. Neulasta (Pegfilgrastim) and Biosimilar Sales Share by Manufacturers in 2025
Figure 14. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Share by Manufacturers in 2025
Figure 15. Neulasta (Pegfilgrastim) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Neulasta (Pegfilgrastim) and Biosimilar Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Neulasta (Pegfilgrastim) and Biosimilar Revenue in 2025
Figure 18. Industry Chain Map of Neulasta (Pegfilgrastim) and Biosimilar
Figure 19. Global Neulasta (Pegfilgrastim) and Biosimilar Market PEST Analysis
Figure 20. Global Neulasta (Pegfilgrastim) and Biosimilar Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Type
Figure 27. Sales Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type (2020-2025)
Figure 28. Sales Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type in 2025
Figure 29. Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type (2020-2025)
Figure 30. Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application
Figure 33. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2020-2025)
Figure 34. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application in 2025
Figure 35. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application (2020-2025)
Figure 36. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application in 2025
Figure 37. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Growth Rate by Application (2020-2025)
Figure 38. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2020-2025)
Figure 39. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region (2020-2025)
Figure 40. North America Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country in 2024
Figure 43. North America Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country in 2024
Figure 45. U.S. Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Neulasta (Pegfilgrastim) and Biosimilar Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Neulasta (Pegfilgrastim) and Biosimilar Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country in 2024
Figure 53. Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country in 2024
Figure 55. Germany Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region in 2024
Figure 67. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region in 2024
Figure 68. China Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (K MT)
Figure 79. South America Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country in 2024
Figure 80. South America Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (M USD)
Figure 81. South America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country in 2024
Figure 82. Brazil Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region in 2024
Figure 92. Saudi Arabia Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Neulasta (Pegfilgrastim) and Biosimilar Production Market Share by Region (2020-2025)
Figure 103. North America Neulasta (Pegfilgrastim) and Biosimilar Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Neulasta (Pegfilgrastim) and Biosimilar Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Neulasta (Pegfilgrastim) and Biosimilar Production (K MT) Growth Rate (2020-2025)
Figure 106. China Neulasta (Pegfilgrastim) and Biosimilar Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share Forecast by Type (2026-2035)
Figure 111. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Application (2026-2035)
Figure 112. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share Forecast by Application (2026-2035)
Figure 1. Product Picture of Neulasta (Pegfilgrastim) and Biosimilar
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD), 2025-2035
Figure 5. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) (2020-2035)
Figure 6. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Neulasta (Pegfilgrastim) and Biosimilar Product Life Cycle
Figure 13. Neulasta (Pegfilgrastim) and Biosimilar Sales Share by Manufacturers in 2025
Figure 14. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Share by Manufacturers in 2025
Figure 15. Neulasta (Pegfilgrastim) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Neulasta (Pegfilgrastim) and Biosimilar Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Neulasta (Pegfilgrastim) and Biosimilar Revenue in 2025
Figure 18. Industry Chain Map of Neulasta (Pegfilgrastim) and Biosimilar
Figure 19. Global Neulasta (Pegfilgrastim) and Biosimilar Market PEST Analysis
Figure 20. Global Neulasta (Pegfilgrastim) and Biosimilar Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Type
Figure 27. Sales Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type (2020-2025)
Figure 28. Sales Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type in 2025
Figure 29. Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type (2020-2025)
Figure 30. Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application
Figure 33. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2020-2025)
Figure 34. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application in 2025
Figure 35. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application (2020-2025)
Figure 36. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application in 2025
Figure 37. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Growth Rate by Application (2020-2025)
Figure 38. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2020-2025)
Figure 39. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region (2020-2025)
Figure 40. North America Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country in 2024
Figure 43. North America Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country in 2024
Figure 45. U.S. Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Neulasta (Pegfilgrastim) and Biosimilar Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Neulasta (Pegfilgrastim) and Biosimilar Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Neulasta (Pegfilgrastim) and Biosimilar Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Neulasta (Pegfilgrastim) and Biosimilar Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country in 2024
Figure 53. Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country in 2024
Figure 55. Germany Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region in 2024
Figure 67. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region in 2024
Figure 68. China Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (K MT)
Figure 79. South America Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country in 2024
Figure 80. South America Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (M USD)
Figure 81. South America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country in 2024
Figure 82. Brazil Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region in 2024
Figure 92. Saudi Arabia Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Neulasta (Pegfilgrastim) and Biosimilar Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Neulasta (Pegfilgrastim) and Biosimilar Production Market Share by Region (2020-2025)
Figure 103. North America Neulasta (Pegfilgrastim) and Biosimilar Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Neulasta (Pegfilgrastim) and Biosimilar Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Neulasta (Pegfilgrastim) and Biosimilar Production (K MT) Growth Rate (2020-2025)
Figure 106. China Neulasta (Pegfilgrastim) and Biosimilar Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share Forecast by Type (2026-2035)
Figure 111. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Forecast by Application (2026-2035)
Figure 112. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share Forecast by Application (2026-2035)
